Why So Many People Look at American Prices
Ozempic (semaglutide) received FDA approval in 2017 and ANVISA approval in Brazil in 2019. Despite this shared timeline, the pricing landscape in each country has never followed the same path. In the United States, Novo Nordisk sets the list price, and patients with insurance coverage often pay very different amounts out of pocket compared to those without. In Brazil, the market operates under different regulatory rules, and Ozempic has never been available through the public healthcare system (SUS). The currency gap between real and dollar adds another layer to consider when making any comparison across borders.
Many Brazilian patients discover that the monthly cost south of the border can seem lower even when paying fully out of pocket, which sparks the question: could importing actually be worth it? Before answering that, you need to look at actual numbers, legal requirements, and all the expenses that show up along the way.